Introducing Our 3-[(1R,2S)-2-Amino-1-Hydroxypropyl]Phenol

Proven Science, Direct from the Source

As a manufacturer who’s spent decades on the shop floor and in the lab, I’ve learned what sets a molecule apart in real-world use. 3-[(1R,2S)-2-Amino-1-Hydroxypropyl]Phenol isn’t just another chemical we added to our inventory because it looked promising in the literature. Fact is, we developed our route for this compound after sitting down with our partners in the pharmaceutical and chemical synthesis industries who needed something that could be counted on — day in, day out. That’s how we ended up refining a process that keeps stereochemistry tight and purity levels above the curve, because performance in synthesis leaves no room for shortcuts or shortcuts show up fast.

What Makes 3-[(1R,2S)-2-Amino-1-Hydroxypropyl]Phenol Stand Out

In practice, this compound has built its name among researchers looking for chiral building blocks with clear downstream functionality. We control the (1R,2S) stereochemistry for a reason. That configuration matters. It plays a crucial role in producing specificity for downstream reactions, and a batch with racemization or even small enantiomeric contamination can derail an entire research project or synthesis campaign. From day one, our approach has been about accuracy — not just hitting the numbers but making those numbers repeatable on each shipment.

The market holds plenty of general phenolic intermediates. Many of them aim to hit a price point, sometimes at the expense of reproducibility or straightforward analytical results. Feedback from chemists has always pointed us back to the importance of keeping analytical traceability transparent and tight. This molecule requires more rigorous attention than most; the stereochemistry alone tells us that. Our plant runs multiple, independent verification steps during synthesis and each lot is released only after chiral HPLC shows consistency batch-over-batch. We don’t just hand out a COA — our team can explain exactly how each lot was made and which decisions influenced purity, yield, and geometric confirmation.

Model and Detailed Specifications

Our product portfolio only includes one grade of 3-[(1R,2S)-2-Amino-1-Hydroxypropyl]Phenol, the model we designate as HAP-12R2S. This choice reflects what we’ve seen with our customers — specialists working with peptide coupling, small-molecule synthesis, and in specific cases, active pharmaceutical ingredient development. The focus remains on a single, high-consistency grade, built off solid-phase and solution-phase production, rather than flooding the market with second-tier variants that confuse the user and create unnecessary risk in scale-up.

Specification-wise, our standard release contains not less than 99% purity by HPLC, while keeping the (1R,2S) ratio over 98%. Water content stays well below 0.5%, controlled by robust drying and storage in a nitrogen atmosphere. We pack under inert to avoid catechol oxidation or amine carbonylation, because leaving that step to the distributor usually comes back to haunt quality on arrival.

Material is delivered as a fine, off-white crystalline powder, with solubility consistent between batches. The melting point occurs within a 1.5°C range on all lots for over five years running. Because our process keeps the synthetic steps minimized, impurity profiles remain simple. We deliberately avoid using halogenated reagents or chromatography media that introduce hard-to-purge side products. Long before we put this on the market, the QC lab ran burn-in tests for storage stability — at room temperature and under refrigerated conditions — so there’d be no rude surprises arriving at the end user’s door.

Key Uses: Chemical Synthesis and More

Much of the demand for 3-[(1R,2S)-2-Amino-1-Hydroxypropyl]Phenol comes from research and manufacturing work in pharma intermediates. The hydroxy/amine setup on the side chain offers multiple entry points for building more complex molecules. We hear from peptide chemists who bring this molecule into custom amino acid analogs or advanced ligands. Others see value in using the phenol end as a hook for further functionalization, especially silencing that hydroxyl with a protection group for later synthetic exploitation.

Some customers work it into key steps for chiral auxiliaries, supporting the build of drug candidates or active moieties in early-stage APIs. Our process avoids any irrelevant chiral pollution, letting these chemists count on batch-to-batch repeatability, crucial if you’re using this building block in an optimizing synthesis that could drain a project budget if the feedstock shifts.

We’ve also seen applications in analytical chemistry, where the molecule acts as a reference or spiking standard — confirming LC-MS instrument response or acting as a control for stereospecific assays. Faculty labs and industrial R&D centers alike wind up choosing our grade because it responds consistently, reproducing chiral separation profiles across most commercial columns.

Working Hands-On to Solve Real Manufacturing Problems

On more than one occasion, partners brought us problems they picked up after buying from the generic supply market. One lab struggled for months with a three-step synthesis because batches arrived with ragged chiral outputs — one lot giving 95% ee, another slipping to 80%. Each failure cost time and forced them to throw out days of work. Finer control over our precursor chemistry made the difference. By using only freshly distilled hydroxyacetone and employing direct amination under strictly monitored conditions, we set a baseline for enantioselective outcomes. These aren’t theoretical adjustments — they turn up directly in sharper consistency from the bench scale through to pilot batches.

Quality issues aren’t always flagged by a lab test. Sometimes a small impurity, invisible on a quick scan, causes delays downstream. We run orthogonal testing: NMR, HPLC, chiral selectors, plus trace element scans when the route involves metallic reagents. On request, we dive even deeper. If a customer faces tough regulatory limits for downstream use, we’ll build in additional releases — for example, checking for residual solvents like DMF or THF, or logging trace heavy metals from any mineral acids used. Any irregularities get fixed at the root, upstream, not masked with last-minute purification.

From our seat in the manufacturing plant, there’s always a trade-off between getting material out the door fast and making sure it’s right. Rushing brings more batch-to-batch variability, even micro-changes that might not show up until the next reaction. Trained eyes in our team oversee every step: not just to hit batch targets but to fix process hiccups before they reach the bottle. We’re not just filling containers for resale — we’re standing behind what goes out the gate, because if assays or reactions don’t run as expected, the blame lands with us.

Differences from Generic and Third-Party Sources

There’s a tangible difference between a product made by a bulk supplier and one built deliberately from raw materials, with full attention to detail. Many intermediates on the open market hit the right chemical structure, but as actual manufacturers, we see the difference in how these materials perform — not just in assays, but when customers actually try to use them.

Outside sources often depend on contract tollers focused on lowest-cost output. Their routes may involve leftover feedstocks, high-temperature steps that encourage side reactions, or incomplete purification. The result: they pass basic identification but present as mixtures when you look closely. We’ve tested direct-sourced lots from several other brands — half the time, side peaks show up on chiral or reversed-phase HPLC that shouldn’t be there.

By contrast, our product starts from whole-molecule synthesis, not post-reaction fractionation. The decision to use only defined, non-halogenated routes stemmed from seeing how hard some byproducts were to remove at the final stage, particularly those with similar polarity to the main product. Our equipment runs strictly segregated — lines for amines and phenolic compounds never cross-contaminate, which stops trace impurities early.

A key question from experienced purchasers concerns supply continuity. Shortcuts taken upstream sometimes backfire: racemate contamination, inconsistent optical rotation, and impurity shifts from changing raw material lots. Our process draws on established, long-term sourcing agreements for precursors we inspect regularly — not only by documentation, but by running small-scale test synthesis to confirm reactivity and trace profile.

One upside to handling only one grade of 3-[(1R,2S)-2-Amino-1-Hydroxypropyl]Phenol under the HAP-12R2S model is that it keeps process variables contained. There’s no give-and-take between product lines, which means we don’t worry about one customer’s spec fix compromising results for the next. Every batch answers to the same thresholds — not just purity, but also for color, particle size, moisture, and chiral integrity.

Supporting the Next Step: Our Commitment to the End User

Nobody in manufacturing should act as if corners only affect the paperwork. The mistakes other suppliers accept as routine — like double-high impurity peaks, off-color, or traces of oxidized side chains — turn up years later in regulatory queries or process rework. We stand ready for customer audits and can give a full batch history for every lot we release. Our culture supports cross-team dialogue between R&D, quality, and production; if a chemist needs extra paperwork for cGMP approval, or more data to meet their own quality system, our team closes the gap without dragging their feet.

Sometimes researchers exploring a new synthesis route want to adjust delivery format: finer or coarser particle size, rejection of certain solvents, or alternative packaging to maximize shelf stability. We’ve adapted on short notice, drawing from experience with similar phenolic and aminopropyl compounds. In these moments, manufacturing flexibility saves projects more than any technical workaround.

We rarely see repeat quality complaints from our direct users. The confidence comes not from chasing rare sales but from engaging with customers who keep coming back with tougher and evolving expectations. Each time the product is used as a core intermediate — whether that’s for pharmaceutical libraries, peptide analogs, or the backbone of new analytical standards — we deliver a consistent tool that speaks for itself in bench success, not just in a regulatory binder.

Building from Experience: Lessons from the Shop Floor

Through many years watching projects rise and fall, some truths remain constant. Customers depend on what comes out of the reactor, not on what suppliers claim. Quality slips happen when accountability drops, when middlemen lose the signal on what actually matters in a material like 3-[(1R,2S)-2-Amino-1-Hydroxypropyl]Phenol. We stay accountable by controlling the process in one location, tracking every control point, and giving end-users a clear route back to the source.

For colleagues and teams embarking on new syntheses, it’s natural to focus on the innovative steps — new ligands, alternate catalytic methods, process scale-ups. Still, each stage falls back on raw materials, often overlooked during early project rush. More than once, we’ve watched ambitious teams run into trouble when time cost from impure feedstocks outweighed any savings on headline price. All those downstream fixes — extra purification, secondary synthesis, troubleshooting reactions — eat more budget than simply selecting the right feed material at the start.

The feedback we welcome most comes when users point out small gains or hidden flaws that only turn up with close, repeated use. These insights drive adjustments in our process and sometimes even inspire a revision to analytical protocols. We treat each request as a learning step — not an annoying outlier, but a chance to make the next batch smoother for all involved.

Continuous Improvement and Solutions for Emerging Challenges

Markets keep changing, with new requirements from regulatory bodies and advances in analytical instrumentation. Sometimes, regulatory changes force a switch toward lower residual solvents or demand evidence on process green-ness. Rather than scramble, we build flexibility into our production: multiple reactors equipped for solvent swaps, DOCs (documented operating conditions) pre-approved for green processes, and open communication between internal compliance and the shop floor. This approach reduces transition pain for both us and our customers.

Not every problem presents itself clearly. From time to time, a user encounters an unexpected variable — a sensitive downstream transformation, or a new analytical protocol turning up peaks not documented before. We set up direct troubleshooting calls between our QC chemists and the client’s analytical team to build a solution grounded in reality, not generic advice. These encounters, even when stressful, create stronger relationships and better outcomes for future users.

Beyond chemical process and supply, we put energy into regulatory and documentation support. Our team keeps abreast of filings, from REACH to next-gen drug master file (DMF) protocols. We monitor updates from global agencies to stay ahead of requirements and to answer customer requests with more than just basic forms. The goal always remains: make meeting compliance standards part of our routine, not a rush job at the finish line.

Final Thoughts from the Manufacturer’s Perspective

Manufacturing 3-[(1R,2S)-2-Amino-1-Hydroxypropyl]Phenol has taught us the impact of working close to both the science and the people putting these molecules to use. Our focus on process control, openness, and a willingness to change based on experience keeps our material relevant and effective for cutting-edge research and development. We approach every batch with the same care, because in this business, a good name lasts longer than any single sale. Every shipment out the gate carries our reputation — and the lessons we’ve learned, one filled order at a time.